Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36(10):1080–6.
Article
Google Scholar
Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014;80(3):435–46.e1.
Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, et al. Interagency registry for mechanically assisted circulatory support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33(1):12–22.
Article
Google Scholar
HVAD System Instructions for Use. HeartWare Inc. Framingham, MA USA 07/18.
HeartMate 3 Left Ventricular Assist System, Instructions for Use. Thoratec Corporation, Pleasanton, CA, USA (08/17).
HeartMate 2 Left Ventricular Assist System, Instructions for Use. Thoratec Corporation, Pleasanton, CA, USA (12/17).
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157–87.
Article
Google Scholar
Baumann Kreuziger LM, Kim B, Wieselthaler GM. Antithrombotic therapy for left ventricular assist devices in adults: a systematic review. J Thromb Haemost. 2015;13(6):946–55.
Article
CAS
Google Scholar
Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Färber G, Hannan MM, et al. 2019 EACTS expert consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019;56(2):230–70.
Article
Google Scholar
Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC, Colombo PC, et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure 2016;376(5):440–50.
Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, et al. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure 2017;376(5):451–60.
Rechenmacher SJ, Fang JC. Bridging anticoagulation: Primum non Nocere. J Am Coll Cardiol. 2015;66(12):1392–403.
Article
CAS
Google Scholar
Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of Pulmonary Embolism. J Am Coll Cardiol. 2016;67(8):976.
Article
Google Scholar
Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the Management of Patients with non–ST-elevation acute coronary syndromes: executive summary. J Am Coll Cardiol. 2014;64(24):2645.
Article
Google Scholar
Kindo M, Gerelli S, Hoang Minh T, Zhang M, Meyer N, Announe T, et al. Exclusive low-molecular-weight heparin as bridging anticoagulant after mechanical valve replacement. Ann Thorac Surg. 2014;97(3):789–95.
Article
Google Scholar
Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation. 2000;101(10):1083–6.
Article
CAS
Google Scholar
Meurin P, Tabet JY, Weber H, Renaud N, Ben DA. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation. 2006;113(4):564–9.
Article
CAS
Google Scholar
Silvestry SC, Joseph SM, Myers SL, Naftel DC, Kirklin JK, Prasad S. LVAD post-implant length of stay impacts long term survival: an Intermacs database analysis. J Heart Lung Transplant. 2017;36(4):S174.
Article
Google Scholar
Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143(5):753–9.
Article
CAS
Google Scholar
Hirsh J. Low molecular weight heparin. Thromb Haemost. 1993;70(1):204–7.
Article
CAS
Google Scholar
Najjar SS, Slaughter MS, Pagani FD, Starling RC, McGee EC, Eckman P, et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 2014;33(1):23–34.
Article
Google Scholar
Shisler DC, Vijayakrishnan R, Lenneman AJ, Birks EJ, Muncy L, Slaughter M, et al. Is bridging anticoagulation required in LVAD patients with subtherapeutic INR? J Heart Lung Transplant. 2017;36(4):S246.
Article
Google Scholar
Borden M, Kiernan MS, Pham DT, DeNofrio D, Sylvia L. Bridging with half-therapeutic dose enoxaparin in outpatients with left ventricular assist devices and sub-therapeutic international normalized ratios. J Heart Lung Transplant. 2015;34(6):860–2.
Article
Google Scholar
Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, et al. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transplant. 2014;33(1):88–93.
Article
Google Scholar
Sandner SE, Zimpfer D, Zrunek P, Steinlechner B, Rajek A, Schima H, et al. Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation. Artif Organs. 2008;32(10):819–22.
Article
CAS
Google Scholar
Meuris B, Arnout J, Vlasselaers D, Schetz M, Meyns B. Long-term management of an implantable left ventricular assist device using low molecular weight heparin and antiplatelet therapy: a possible alternative to oral anticoagulants. Artif Organs. 2007;31(5):402–5.
Article
Google Scholar
Bhatia A, Juricek C, Sarswat N, Adatya S, Kim G, Sayer G, et al. Increased risk of bleeding in left ventricular assist device patients treated with enoxaparin as bridge to therapeutic international normalized ratio. ASAIO J. 2018;64(2):140–6.
Article
CAS
Google Scholar